LifeStance Health Group, Inc. (NASDAQ:LFST) Receives Consensus Recommendation of “Hold” from Brokerages

Shares of LifeStance Health Group, Inc. (NASDAQ:LFST) have been assigned an average rating of “Hold” from the five ratings firms that are currently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and one has issued a buy recommendation on the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $8.60.

Several equities research analysts have recently commented on LFST shares. The Goldman Sachs Group increased their price objective on LifeStance Health Group from $8.00 to $9.00 and gave the company a “neutral” rating in a report on Monday, March 4th. Barclays increased their price objective on LifeStance Health Group from $7.00 to $8.00 and gave the company an “underweight” rating in a report on Thursday, February 29th. Jefferies Financial Group increased their price objective on LifeStance Health Group from $8.00 to $9.00 and gave the company a “buy” rating in a report on Wednesday, March 6th. Finally, Morgan Stanley reissued an “overweight” rating and issued a $10.00 price objective on shares of LifeStance Health Group in a report on Monday.

Insider Buying and Selling at LifeStance Health Group

In other LifeStance Health Group news, insider Danish J. Qureshi sold 12,965 shares of the firm’s stock in a transaction on Monday, April 1st. The stock was sold at an average price of $5.93, for a total transaction of $76,882.45. Following the completion of the sale, the insider now owns 4,911,050 shares of the company’s stock, valued at approximately $29,122,526.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, insider Danish J. Qureshi sold 12,965 shares of LifeStance Health Group stock in a transaction on Monday, April 1st. The stock was sold at an average price of $5.93, for a total transaction of $76,882.45. Following the completion of the sale, the insider now owns 4,911,050 shares of the company’s stock, valued at $29,122,526.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Kevin Michael Mullins sold 115,136 shares of LifeStance Health Group stock in a transaction on Friday, March 1st. The stock was sold at an average price of $8.02, for a total value of $923,390.72. Following the sale, the insider now directly owns 4,575,480 shares of the company’s stock, valued at approximately $36,695,349.60. The disclosure for this sale can be found here. Insiders sold 245,463 shares of company stock valued at $1,786,868 in the last quarter. 8.50% of the stock is currently owned by insiders.

Institutional Investors Weigh In On LifeStance Health Group

Hedge funds and other institutional investors have recently modified their holdings of the company. Jennison Associates LLC lifted its holdings in shares of LifeStance Health Group by 35.4% during the third quarter. Jennison Associates LLC now owns 2,046,358 shares of the company’s stock worth $14,058,000 after buying an additional 535,358 shares in the last quarter. FMR LLC increased its position in shares of LifeStance Health Group by 6.7% in the third quarter. FMR LLC now owns 28,178,666 shares of the company’s stock worth $193,587,000 after purchasing an additional 1,758,427 shares during the period. SG Americas Securities LLC bought a new position in shares of LifeStance Health Group in the third quarter worth $206,000. Principal Financial Group Inc. increased its position in shares of LifeStance Health Group by 4.5% in the third quarter. Principal Financial Group Inc. now owns 3,895,887 shares of the company’s stock worth $26,765,000 after purchasing an additional 168,091 shares during the period. Finally, DekaBank Deutsche Girozentrale bought a new position in shares of LifeStance Health Group in the third quarter worth $34,000. Institutional investors and hedge funds own 85.50% of the company’s stock.

LifeStance Health Group Stock Up 3.5 %

Shares of LFST traded up $0.20 during mid-day trading on Monday, hitting $5.91. 519,671 shares of the company’s stock were exchanged, compared to its average volume of 1,299,068. The company has a market cap of $2.25 billion, a PE ratio of -11.59 and a beta of 1.34. LifeStance Health Group has a 52 week low of $4.74 and a 52 week high of $9.59. The company has a 50-day simple moving average of $6.51 and a 200 day simple moving average of $6.54. The company has a debt-to-equity ratio of 0.20, a current ratio of 1.11 and a quick ratio of 1.11.

LifeStance Health Group (NASDAQ:LFST) last issued its quarterly earnings results on Wednesday, February 28th. The company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.03). The business had revenue of $280.60 million for the quarter, compared to the consensus estimate of $263.14 million. LifeStance Health Group had a negative return on equity of 12.66% and a negative net margin of 17.64%. On average, research analysts forecast that LifeStance Health Group will post -0.3 earnings per share for the current fiscal year.

About LifeStance Health Group

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.